206 related articles for article (PubMed ID: 28036263)
21. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer.
Kim H; Kwon YM; Kim JS; Lee H; Park JH; Shim YM; Han J; Park J; Kim DH
J Clin Oncol; 2004 Jun; 22(12):2363-70. PubMed ID: 15197197
[TBL] [Abstract][Full Text] [Related]
22. The association between RARβ and FHIT promoter methylation and the carcinogenesis of patients with cervical carcinoma: A meta-analysis.
Shu R; He J; Wu C; Gao J
Tumour Biol; 2017 Jun; 39(6):1010428317709126. PubMed ID: 28639889
[TBL] [Abstract][Full Text] [Related]
23. Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma.
Hsu HS; Chen TP; Hung CH; Wen CK; Lin RK; Lee HC; Wang YC
Cancer; 2007 Nov; 110(9):2019-26. PubMed ID: 17876837
[TBL] [Abstract][Full Text] [Related]
24. c-Myc suppresses microRNA-29b to promote tumor aggressiveness and poor outcomes in non-small cell lung cancer by targeting FHIT.
Wu DW; Hsu NY; Wang YC; Lee MC; Cheng YW; Chen CY; Lee H
Oncogene; 2015 Apr; 34(16):2072-82. PubMed ID: 24909176
[TBL] [Abstract][Full Text] [Related]
25. Promoter methylation status of the FHIT gene and Fhit expression: association with HER2/neu status in breast cancer patients.
Jeong YJ; Jeong HY; Lee SM; Bong JG; Park SH; Oh HK
Oncol Rep; 2013 Nov; 30(5):2270-8. PubMed ID: 23969757
[TBL] [Abstract][Full Text] [Related]
26. Establishment of two data mining models of lung cancer screening based on three gene promoter methylations combined with telomere damage.
Wang W; Feng X; Duan X; Tan S; Wang S; Wang T; Feng F; Wu Y; Wu Y
Int J Biol Markers; 2017 Mar; 32(1):e141-e146. PubMed ID: 27716889
[TBL] [Abstract][Full Text] [Related]
27. Association between P(16INK4a) promoter methylation and non-small cell lung cancer: a meta-analysis.
Gu J; Wen Y; Zhu S; Hua F; Zhao H; Xu H; You J; Sun L; Wang W; Chen J; Zhou Q
PLoS One; 2013; 8(4):e60107. PubMed ID: 23577085
[TBL] [Abstract][Full Text] [Related]
28. FHIT, EGFR, and MSH2: possible etiopathologic, prognostic, and predictive role in non-small cell lung carcinoma in Egyptian patients.
Younes SF; Aiad HA; Asaad NY; Kandil MA; Natkunam Y; Mokhtar NM
Appl Immunohistochem Mol Morphol; 2014 Apr; 22(4):275-83. PubMed ID: 24185125
[TBL] [Abstract][Full Text] [Related]
29. [Methylation status of the 5' CpG islands in FHIT gene in the plasma and tissues of cervical cancer patients].
Ren CC; Miao XH; Yang B; Zhao L; Sun R; Song WQ
Yi Chuan; 2006 Sep; 28(9):1061-6. PubMed ID: 16963412
[TBL] [Abstract][Full Text] [Related]
30. Aberrant gene promoter methylation of p16, FHIT, CRBP1, WWOX, and DLC-1 in Epstein-Barr virus-associated gastric carcinomas.
He D; Zhang YW; Zhang NN; Zhou L; Chen JN; Jiang Y; Shao CK
Med Oncol; 2015 Apr; 32(4):92. PubMed ID: 25720522
[TBL] [Abstract][Full Text] [Related]
31. The clinicopathological significance and drug target potential of FHIT in breast cancer, a meta-analysis and literature review.
Su Y; Wang X; Li J; Xu J; Xu L
Drug Des Devel Ther; 2015; 9():5439-45. PubMed ID: 26491255
[TBL] [Abstract][Full Text] [Related]
32. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer.
Iliopoulos D; Guler G; Han SY; Johnston D; Druck T; McCorkell KA; Palazzo J; McCue PA; Baffa R; Huebner K
Oncogene; 2005 Feb; 24(9):1625-33. PubMed ID: 15674328
[TBL] [Abstract][Full Text] [Related]
33. [Correlation between methylation of 5'-CpG islands and inactivation of FHIT gene in cervical cancer].
Shi HR; Wu QH; Suo ZH; Nesland JM
Ai Zheng; 2005 Jan; 24(1):7-11. PubMed ID: 15642192
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological significance of aberrant methylation of RARbeta2 at 3p24, RASSF1A at 3p21.3, and FHIT at 3p14.2 in patients with non-small cell lung cancer.
Tomizawa Y; Iijima H; Nomoto T; Iwasaki Y; Otani Y; Tsuchiya S; Saito R; Dobashi K; Nakajima T; Mori M
Lung Cancer; 2004 Dec; 46(3):305-12. PubMed ID: 15541815
[TBL] [Abstract][Full Text] [Related]
35. System analysis of
Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
[TBL] [Abstract][Full Text] [Related]
36. CpG island methylator phenotype involving chromosome 3p confers an increased risk of non-small cell lung cancer.
Liu Z; Li W; Lei Z; Zhao J; Chen XF; Liu R; Peng X; Wu ZH; Chen J; Liu H; Zhou QH; Zhang HT
J Thorac Oncol; 2010 Jun; 5(6):790-7. PubMed ID: 20521346
[TBL] [Abstract][Full Text] [Related]
37. Hypermethylation of the 5' CpG island of the FHIT gene is associated with hyperdiploid and translocation-negative subtypes of pediatric leukemia.
Zheng S; Ma X; Zhang L; Gunn L; Smith MT; Wiemels JL; Leung K; Buffler PA; Wiencke JK
Cancer Res; 2004 Mar; 64(6):2000-6. PubMed ID: 15026336
[TBL] [Abstract][Full Text] [Related]
38. Association of the promoter methylation and protein expression of Fragile Histidine Triad (FHIT) gene with the progression of differentiated thyroid carcinoma.
Yin DT; Wang L; Sun J; Yin F; Yan Q; Shen R; He G; Gao JX
Int J Clin Exp Pathol; 2010 May; 3(5):482-91. PubMed ID: 20606729
[TBL] [Abstract][Full Text] [Related]
39. 5'-CpG island methylation of the FHIT gene is associated with reduced protein expression and higher clinical stage in cervical carcinomas.
Wu Q; Shi H; Suo Z; Nesland JM
Ultrastruct Pathol; 2003; 27(6):417-22. PubMed ID: 14660280
[TBL] [Abstract][Full Text] [Related]
40. FHIT
Da Silva J; Jouida A; Ancel J; Dalstein V; Routhier J; Delepine G; Cutrona J; Jonquet A; Dewolf M; Birembaut P; Deslée G; Polette M; Nawrocki-Raby B
J Pathol; 2020 Jun; 251(2):187-199. PubMed ID: 32237123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
